热门资讯> 正文
Sensei Biotherapeutics GAAP每股收益为-16.72美元
2026-03-30 19:37
- Sensei Biotherapeutics press release (SNSE): FY GAAP EPS of -$16.72.
- Cash, cash equivalents and marketable securities were $21.2 million as of December 31, 2025 as compared to $41.3 million as of December 31, 2024.
More on Sensei Biotherapeutics
- Sensei Biotherapeutics, Inc. (SNSE) Faeth Therapeutics, Inc. - M&A Call - Slideshow
- Nano-cap biotech Sensei surges on $200M private placement, acquisition
- Seeking Alpha’s Quant Rating on Sensei Biotherapeutics
- Historical earnings data for Sensei Biotherapeutics
- Financial information for Sensei Biotherapeutics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。